While DNA-based HRD biomarkers have demonstrated some preliminary evidence in predicting PARP inhibitor response outside of breast and ovarian cancer [17–19], these methods have only demonstrated clinical utility in ovarian cancer [20, 21]—with significant ongoing research for breast cancer [16, 22–24]—necessitating new approaches for other cancer types. This evidence concerns the gene PARP1 and ovarian carcinoma.